Alzheimer’s Drug Researchers with ADDF Grants Gaining Access to New Services

Alzheimer’s Drug Researchers with ADDF Grants Gaining Access to New Services
PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s drug discovery programs. Through the collabortion, PsychoGenics will offer its products and services to ADDF-funded biotechnology companies on "extremely favorable financial terms" through risk-sharing agreements, which has the effect of increasing an ADDF grant's value. "We are delighted to collaborate with PsychoGenics to make its expertise and services available to our Alzheimer's research community. This beneficial partnership will allow our
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *